长期白蛋白治疗用于失代偿性肝硬化研究新进展

摘要/Abstract

摘要： 人血白蛋白(HA)常被用于治疗肝硬化和腹水患者,与常见的急性或短期在住院期间使用HA相比,长期使用HA对于绝大多数出院后长期门诊随访的患者存在获益不确定和用药不规律、成本较高、输注不方便等问题。近几年进行了多项长期HA治疗的随机对照试验以确定该治疗的临床获益和卫生经济学获益,其中ANSWER研究发现长期HA的合理使用能够减少住院率,节约总医疗费用、降低并发症和死亡率。本文中,我们将分析HA治疗肝硬化和腹水的现有临床研究数据,重点关注多项研究之间存在的人群差异和给药方式和疗程的差异、结合HA治疗机制方面的最新研究进展来解释相关数据差异,给长期HA治疗未来的前景提供参考。

关键词: 肝硬化, 腹水, 有效白蛋白, 长期HA治疗

李伟. 长期白蛋白治疗用于失代偿性肝硬化研究新进展[J]. 肝脏, 2022, 27(6): 617-619.

参考文献

[1] Strauss AW, Donohue AM, Bennett CD, et al. Rat liver preproalbumin: in vitro synthesis and partial amino acid sequence. Proc Natl Acad Sci USA,1977,74:1358-1362.
[2] Bernardi M, Angeli P, Claria J, et al. Albumin indecompensated cirrhosis: new concepts and perspectives. Gut,2020,69:1127-1138.
[3] Arroyo V, García-Martinez R, Salvatella X. Human serum albumin, systemic inflammation, and cirrhosis. J Hepatol,2014,6:396-407.
[4] Fernández J, Clària J, Amorós A, et al. Effects of albumin treatment on systemic and portal hemodynamics and systemic inflammation in patients with decompensated cirrhosis. Gastroenterology,2019;157:149-162.
[5] Garcia-Martinez R, Caraceni P, Bernardi M, et al. Albumin: pathophysiologic basis of its role in the treatment of cirrhosis and its complications. Hepatology,2013,58:1836-1846.
[6] Bortoluzzi A, Ceolotto G, Gola E, et al. Positive cardiac inotropic effect of albumin infusion in rodents with cirrhosis and ascites: molecular mechanisms. Hepatology,2013,57(1):266-276.
[7] D’Amico G, Maruzzelli L, Airoldi A, et al. Performance of the model for end-stage liver disease score for mortality prediction and the potential role of etiology. J Hepatol, 2021,75:1355-1366.
[8] Naldi M, Baldassarre M, Domenicali M, et al. Structural and functional integrity of human serum albumin: Analytical approaches and clinical relevance in patients with liver cirrhosis. J Pharm Biomed Anal,2017,144:138-153.
[9] Jagdish RK, Maras JS, Sarin SK. Albumin in Advanced Liver Diseases: The Good and Bad of a Drug! Hepatology,2021,74(5):2848-2862.
[10] Clària J, Stauber RE, Coenraad MJ, et al. CANONIC Study Investigators of the EASL-CLIF Consortium and the European Foundation for the Study of Chronic Liver Failure (EF-CLIF). Systemic inflammation in decompensated cirrhosis: Characterization and role in acute-on-chronic liver failure. Hepatology,2016,64(4):1249-1264.
[11] Alcaraz-Quiles J, Casulleras M, Oettl K, et al. Oxidized albumin triggers a cytokine storm in leukocytes through p38 mitogen-activated protein kinase: role in systemic inflammation in decompensated cirrhosis. Hepatology,2018,68:1937-1952.
[12] Das S, Maras JS, Hussain MS, et al. Hyperoxidized albumin modulates neutrophils to induce oxidative stress and inflammation in severe alcoholic hepatitis. Hepatology,2017,65:631-646.
[13] Baldassarre M, Naldi M, Zaccherini G, et al. Determination of Effective Albumin in Patients With Decompensated Cirrhosis: Clinical and Prognostic Implications. Hepatology,2021, 74(4):2058-2073.
[14] European Association for the Study of the Liver. EASL clinical practice guidelines for the management of patients wit decompensated cirrhosis. J Hepatol,2018,69:406-460.
[15] Caraceni P, Riggio O, Angeli P, et al. ANSWER Study Investigators. Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial. Lancet, 2018,391(10138):2417-2429.
[16] Caraceni P, Tufoni M, Zaccherini G, et al.On-treatment serum albumin level can guide long-term treatment in patients with cirrhosis and uncomplicated ascites. J Hepatol, 2021,74:340-349.
[17] China L, Freemantle N, Forrest E, et al. ATTIRE Trial Investigators. A Randomized Trial of Albumin Infusions in Hospitalized Patients with Cirrhosis. N Engl J Med,2021,384(9):808-817.
[18] Solà E, Solé C, Simón-Talero M, et al. Midodrine and albumin for prevention of complications in patients with cirrhosis awaiting liver transplantation. A randomized placebo-controlled trial. J Hepatol,2018,69(6):1250-1259.
[19] Di Pascoli M, Fasolato S, Piano S, et al. Long-term administration of human albumin improves survival in patients with cirrhosis and refractory ascites. Liver Int,2019,39(1):98-105.
[20] Fernández J, Clària J, Amorós A, et al. Effects of Albumin Treatment on Systemic and Portal Hemodynamics and Systemic Inflammation in Patients With Decompensated Cirrhosis. Gastroenterology,2019,157(1):149-162.